- ISIN
- US78464A8707
- CUSIP
- 78464A870
- Issuer
- State Street
- Inception Date
- Feb 6, 2006
- Region
- North America (U.S.)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- S&P Biotechnology Select Industry Index
- Domicile
- United States
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Multi-Cap
- Asset Class Style
- Growth
- Assets Under Management
- $8B
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XBI Performance Chart
SPDR S&P Biotech ETF (XBI) is up 11.0% since the beginning of the year. XBI is currently trading at $135 per share. Investors who bought $1,000 worth of XBI shares 5 years ago would now be looking at an investment worth $1,013.
Loading charts...
Returns By Period
SPDR S&P Biotech ETF (XBI) has returned 11.00% so far this year and 62.93% over the past 12 months. Over the last ten years, XBI has returned 9.90% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
SPDR S&P Biotech ETF
- 1D
- -0.78%
- 1M
- 3.56%
- YTD
- 11.00%
- 6M
- 11.29%
- 1Y
- 62.93%
- 3Y*
- 15.78%
- 5Y*
- 0.25%
- 10Y*
- 9.90%
Benchmark (S&P 500 Index)
- 1D
- -0.57%
- 1M
- 1.39%
- YTD
- 9.73%
- 6M
- 10.46%
- 1Y
- 24.50%
- 3Y*
- 19.43%
- 5Y*
- 12.21%
- 10Y*
- 13.75%
XBI Monthly Returns History
Based on dividend-adjusted daily data since Feb 6, 2006, XBI's average daily return is +0.06%, while the average monthly return is +1.18%. At this rate, an investment would double in approximately 4.9 years.
Historically, 56% of months were positive and 44% were negative. The best month was Apr 2020 with a return of +20.6%, while the worst month was Jan 2016 at -28.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, XBI closed higher 52% of trading days. The best single day was Oct 13, 2008 with a return of +18.1%, while the worst single day was Mar 16, 2020 at -12.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.31% | 2.10% | 0.28% | 2.82% | 4.08% | -0.99% | 11.00% | ||||||
| 2025 | 2.90% | -4.27% | -8.57% | 2.28% | -4.53% | 4.73% | 3.29% | 4.89% | 11.55% | 12.49% | 9.27% | -0.67% | 35.89% |
| 2024 | -2.08% | 12.57% | -3.59% | -10.82% | 5.33% | 4.15% | 6.85% | 2.22% | -2.41% | -1.79% | 2.67% | -9.59% | 1.01% |
| 2023 | 7.11% | -6.81% | -8.01% | 5.24% | 4.64% | -0.85% | 1.31% | -6.04% | -7.80% | -9.30% | 14.03% | 18.25% | 7.60% |
| 2022 | -16.55% | -3.85% | 0.06% | -17.86% | -6.84% | 7.98% | 9.24% | 3.17% | -5.23% | 3.57% | 1.79% | -0.74% | -25.87% |
| 2021 | 8.59% | -3.19% | -8.32% | 0.72% | -6.24% | 5.70% | -8.86% | 7.64% | -5.37% | -0.72% | -6.84% | -3.71% | -20.45% |
Benchmark Metrics
SPDR S&P Biotech ETF has an annualized alpha of 4.54%, beta of 1.02, and R2 of 0.42 versus S&P 500 Index. Calculated based on daily prices since February 06, 2006.
- This ETF captured 113.45% of S&P 500 Index gains and 104.22% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.42 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 4.54%
- Beta
- 1.02
- R²
- 0.42
- Upside Capture
- 113.45%
- Downside Capture
- 104.22%
Expense Ratio
XBI has an expense ratio of 0.35%, placing it in the medium range.
Return for Risk
Risk / Return Rank
XBI ranks 83 for risk / return — in the top 83% of ETFs on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XBI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.44 | ||
| Sortino ratioReturn per unit of downside risk | +0.56 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.36 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 6.51 | 2.71 | +3.80 |
| Martin ratioReturn relative to average drawdown | 19.22 | 12.15 | +7.07 |
Dividends
Dividend History
SPDR S&P Biotech ETF provided a 0.33% dividend yield over the last twelve months, with an annual payout of $0.44 per share. The fund has been increasing its distributions for 2 consecutive years.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.44 | $0.45 | $0.13 | $0.02 | $0.00 | $0.04 | $0.28 | $0.00 | $0.20 | $0.20 | $0.15 | $0.43 |
Dividend yield | 0.33% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Monthly Dividends
The table displays the monthly dividend distributions for SPDR S&P Biotech ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.03 | $0.00 | $0.00 | $0.41 | $0.45 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.11 | $0.00 | $0.00 | $0.02 | $0.00 | $0.00 | $0.00 | $0.13 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.02 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.04 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.04 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the SPDR S&P Biotech ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the SPDR S&P Biotech ETF was 63.89%, occurring on May 11, 2022. The portfolio has not yet recovered.
The current SPDR S&P Biotech ETF drawdown is 21.78%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -63.89%May 2022 | 1y 3mo | — | 5y 4moFeb 2021 - now |
2016 bear market2016 | -49.25%Feb 2016 | 6mo 26d | 1y 11mo | 2y 5moJul 2015 - Jan 2018 |
Financial crisis2007–2009 | -37.67%Mar 2009 | 6mo 22d | 2y 1mo | 2y 8moAug 2008 - Apr 2011 |
Rate-hike selloffLate 2018 | -35.26%Dec 2018 | 6mo 6d | 1y 4mo | 1y 10moJun 2018 - May 2020 |
2014 bear market2014 | -29.07%May 2014 | 2mo 9d | 5mo 23d | 8mo 2dFeb 2014 - Oct 2014 |
Drawdown Indicators
| XBI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -56.78% | -7.11% |
Max Drawdown (1Y)Largest decline over 1 year | -9.72% | -9.10% | -0.62% |
Max Drawdown (3Y)Largest decline over 3 years | -32.99% | -18.90% | -14.09% |
Max Drawdown (5Y)Largest decline over 5 years | -54.71% | -25.43% | -29.28% |
Max Drawdown (10Y)Largest decline over 10 years | -63.89% | -33.92% | -29.97% |
Current DrawdownCurrent decline from peak | -21.78% | -1.29% | -20.49% |
Average DrawdownAverage peak-to-trough decline | -20.93% | -10.72% | -10.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.29% | 2.02% | +1.27% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with XBI
Add SPDR S&P Biotech ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XBI